Natalia Aptsiauri
Overview
Explore the profile of Natalia Aptsiauri including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
36
Citations
1436
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Garrido M, Navarro-Ocon A, Ronco-Diaz V, Olea N, Aptsiauri N
Genes (Basel)
. 2025 Jan;
15(12.
PMID: 39766811
Major histocompatibility complex (MHC) class-I molecules (or Human Leucocyte Antigen class-I) play a key role in adaptive immunity against cancer. They present specific tumor neoantigens to cytotoxic T cells and...
2.
Molina-Alejandre M, Perea F, Calvo V, Martinez-Toledo C, Nadal E, Sierra-Rodero B, et al.
J Immunother Cancer
. 2024 Oct;
12(10).
PMID: 39428126
Background: Loss of human leukocyte antigen (HLA) class I expression and loss of heterozygosity (LOH) are common events implicated in the primary resistance of non-small cell lung cancer (NSCLC) to...
3.
Aptsiauri N, Garrido F
Clin Cancer Res
. 2022 Jul;
28(23):5021-5029.
PMID: 35861868
HLA class I molecules are key in tumor recognition and T cell-mediated elimination. Loss of tumor HLA class I expression with different underlying molecular defects results in reduced antigen presentation...
4.
Navarro-Ocon A, Blaya-Canovas J, Lopez-Tejada A, Blancas I, Sanchez-Martin R, Garrido M, et al.
Pharmaceutics
. 2022 Mar;
14(3).
PMID: 35335881
Breast cancer is the most common type of malignancy and leading cause of cancer death among women worldwide. Despite the current revolutionary advances in the field of cancer immunotherapy, clinical...
5.
Garrido M, Perea F, Vilchez J, Rodriguez T, Anderson P, Garrido F, et al.
Cancers (Basel)
. 2021 Oct;
13(20).
PMID: 34680201
Total or partial loss of class I antigens reduce the recognition of specific tumor peptides by cytotoxic T lymphocytes favoring cancer immune escape during natural tumor evolution. These alterations can...
6.
Gil-Julio H, Perea F, Rodriguez-Nicolas A, Cozar J, Gonzalez-Ramirez A, Concha A, et al.
Int J Mol Sci
. 2021 Jul;
22(14).
PMID: 34298868
Cancer eradication and clinical outcome of immunotherapy depend on tumor cell immunogenicity, including HLA class I (HLA-I) and PD-L1 expression on malignant cells, and on the characteristics of the tumor...
7.
Anderson P, Aptsiauri N, Ruiz-Cabello F, Garrido F
Cell Mol Immunol
. 2021 Jan;
18(3):556-565.
PMID: 33473191
T cell-mediated immune therapies have emerged as a promising treatment modality in different malignancies including colorectal cancer (CRC). However, only a fraction of patients currently respond to treatment. Understanding the...
8.
Garrido F, Aptsiauri N
Immunology
. 2019 Sep;
158(4):255-266.
PMID: 31509607
Tumours can escape T-cell responses by losing major histocompatibility complex (MHC)/ human leucocyte antigen (HLA) class I molecules. In the early stages of cancer development, primary tumours are composed of...
9.
Flores-Martin J, Perea F, Exposito-Ruiz M, Carretero F, Rodriguez T, Villamediana M, et al.
Ann Surg Oncol
. 2019 Apr;
26(8):2631-2639.
PMID: 31011905
Background: Tumor human leukocyte antigen class I (HLA-I) expression plays an important role in T cell-mediated tumor rejection. Loss of HLA-I is associated with cancer progression and resistance to immunotherapy,...
10.
Garrido M, Rodriguez T, Zinchenko S, Maleno I, Ruiz-Cabello F, Concha A, et al.
Immunogenetics
. 2018 Aug;
70(10):647-659.
PMID: 30145665
HLA class I (HLA-I) molecules play a crucial role in the presentation of tumor antigenic peptides to CD8+ T cells. Tumor HLA-I loss provides a route of immune escape from...